Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM2RX0I)

• Drug Name: Abametapir Drug Info
• Synonyms: 5,5'-Dimethyl-2,2'-bipyridine; 1762-34-1; 5,5'-Dimethyl-2,2'-dipyridyl; 5,5'-Dimethyl-2,2'-bipyridyl; 6,6'-Bi-3-picoline; 2,2'-BIPYRIDINE, 5,5'-DIMETHYL-; HA-44; 6,6'-Di-3-picolyl; 6,6'-Di-3-picoline; UNII-6UO390AMFB; 5-methyl-2-(5-methylpyridin-2-yl)pyridine; MFCD01740554; 6UO390AMFB; CHEMBL2205807; 5,5'-dimethyl-2,2'-bipyridinyl; 5,5 -Dimethyl-2,2 -bipyridine; Xeglyze; BRN 0123183; Abametapir [USAN:INN]; Xeglyze(Abametapir); Xeglyze (TN); PubChem24353; Abametapir (USAN/INN); ACMC-209eb4; SCHEMBL351152; HA44; 2,2 -Bis-(5-methylpyridyl); DTXSID00170095; ZINC403335; 9238AA; ANW-22814; BDBM50401351; LT0042; s5752; 5,5''-Dimethyl-2,2''-bipyridine; AKOS005257775; CS-W004546; DB11932; MCULE-8581798506; SB17220; 5,5 inverted exclamation marka-Dimethyl-2,2 inverted exclamation marka-dipyridyl; 5,5'-Dimethyl-2,2'-dipyridyl, 98%; AK-63331; DS-15219; SY052805; FT-0689891; D10687; W-108621; Q27265547; 5,5 inverted exclamation mark -Dimethyl-2,2 inverted exclamation mark -bipyridyl

Indication

Disease Entry	ICD 11	Status	REF
Head and body lice	1G00.0	Approved	[1]

• Cross-matching ID:
  PubChem CID: 15664
  CAS Number: CAS 1762-34-1
  TTD Drug ID: DM2RX0I
  ACDINA Drug ID: D00802

Molecule-Related Drug Atlas

Drug(s) Targeting Matrix metalloproteinase (MMP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BLZ-100	DMFKA4G	Glioma	2A00.0	Phase 1/2	[2]
S-3304	DMCBQTF	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[3]
ABT-518	DMA2RM3	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[4]
D-1927	DM5D8JW	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[5]
S-3536	DMZYRI3	Osteoarthritis	FA00-FA05	Discontinued in Phase 1	[6]
BB-2983	DMYK8OG	Inflammatory bowel disease	DD72	Discontinued in Phase 1	[7]
ONO-4817	DMKRVUN	Inflammatory bowel disease	DD72	Discontinued in Phase 1	[8]
DFD-11	DMHXVN1	Head and body lice	1G00.0	Application submitted	[9]
D-9120	DMHNZ1P	Inflammatory bowel disease	DD72	Terminated	[10]
D-5410	DMXHN6U	Rheumatoid arthritis	FA20	Terminated	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Matrix metalloproteinase (MMP)	TT1GHVO	NOUNIPROTAC	Inhibitor	[1]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [3] Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers. Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93.
• [4] Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry. J Mass Spectrom. 2004 Mar;39(3):277-88.
• [5] Correlation of antiangiogenic and antitumor efficacy of N-biphenyl sulfonyl-phenylalanine hydroxiamic acid (BPHA), an orally-active, selective matrix metalloproteinase inhibitor. Cancer Res. 1999 Mar15;59(6):1231-5.
• [6] CIINE Reflects Collagenase-Specific CII Breakdown in Cartilage Explant and Whole Body of Canine. Biomark Insights. 2013; 8: 77-83.
• [7] Matrix metalloproteinase inhibition reduces intimal hyperplasia in a porcine arteriovenous-graft model. J Vasc Surg. 2004 Feb;39(2):432-9.
• [8] ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res. 2000 Apr;49(4):144-6.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] WO patent application no. 2006,1139,93, Matrix metalloproteinase inhibitors of tgfss -induced subcapsular cataract formation.
• [11] US patent application no. US20080187572 A1.